eFFECTOR Therapeutics, Inc.
11180 Roselle Street
Suite A
San Diego
California
92121
United States
About eFFECTOR Therapeutics, Inc.
84 articles about eFFECTOR Therapeutics, Inc.
-
eFFECTOR Therapeutics to Participate in Upcoming April 2024 Investor Conference
4/9/2024
eFFECTOR Therapeutics, Inc., a leader in the development of selective translation regulator inhibitors for the treatment of cancer, announced that the Company will present at the Stifel Virtual Oncology Forum on Tuesday, April 16th at 11:30 am ET.
-
eFFECTOR Therapeutics Announces Topline Results of Phase 2 KICKSTART Trial of Tomivosertib Combined with Pembrolizumab in Non-Small Cell Lung Cancer
4/4/2024
eFFECTOR Therapeutics, Inc. today announced topline results from the primary analysis of the randomized Phase 2 KICKSTART trial which tested tomivosertib or placebo, each combined with pembrolizumab, as frontline treatment for patients with non-small cell lung cancer (NSCLC) with PD-L1 ≥50%.
-
Drugmakers are testing a variety of biologics and small molecules in conjunction with therapies aimed at modulating the immune system to target and destroy cancer cells.
-
eFFECTOR Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Corporate Update
3/25/2024
eFFECTOR Therapeutics, Inc. (NASDAQ: EFTR), a leader in the development of selective translation regulator inhibitors (STRIs) for the treatment of cancer, today reported financial results for the fourth quarter and year ended December 31, 2023, and provided a corporate update.
-
The progression-free survival metric has helped shepherd many products across the regulatory finish line. Experts say the FDA’s new emphasis on overall survival will be felt especially by small biotechs.
-
eFFECTOR Therapeutics to Present at Oppenheimer 34th Annual Healthcare Life Sciences Conference
2/5/2024
eFFECTOR Therapeutics, Inc. (NASDAQ: EFTR) today announced that Steve Worland, Ph.D., president, and chief executive officer of eFFECTOR, will present at the Oppenheimer 34th Annual Healthcare Life Sciences Conference on Wednesday, February 14th at 10:40 am ET.
-
eFFECTOR Therapeutics to Host Virtual Investor R&D Day on January 24, 2024
1/9/2024
eFFECTOR Therapeutics, Inc. (NASDAQ: EFTR), a leader in the development of selective translation regulator inhibitors (“STRIs”) for the treatment of cancer, today announced that it will host a virtual investor R&D Day on Wednesday, January 24, 2024, at 4:30 pm ET.
-
eFFECTOR Therapeutics Announces Reverse Stock SplitEFTR common stock expected to begin trading on a split-adjusted basis on January 12, 2024
1/9/2024
eFFECTOR Therapeutics, Inc., a leader in the development of selective translation regulator inhibitors for the treatment of cancer, announced that its Board of Directors has approved a 1-for-25 reverse stock split of the Company’s common stock.
-
eFFECTOR Therapeutics Announces New Positive Interim Data from Dose Escalation and Phase 2 Expansion Cohorts of Zotatifin in ER+ Metastatic Breast Cancer Patients
12/8/2023
eFFECTOR Therapeutics, Inc. today announced new positive interim data from dose escalation and Phase 2 expansion cohorts of a Phase 1/2 clinical study of zotatifin in patients with estrogen receptor positive (ER+) metastatic breast cancer (mBC).
-
eFFECTOR Receives U.S. FDA Fast Track Designation for Zotatifin in Combination with Fulvestrant and Abemaciclib for Treatment of ER+/HER2- Advanced Metastatic Breast Cancer
11/28/2023
eFFECTOR Therapeutics, Inc. today announced that the U.S. Food and Drug Administration (FDA) has granted Fast Track designation for zotatifin.
-
eFFECTOR to Present New Clinical Data from Dose Escalation and Phase 2 Expansion Cohorts of Zotatifin in Patients with ER+ Metastatic Breast Cancer at SABCS 2023 Annual Meeting
11/15/2023
eFFECTOR Therapeutics, Inc. (NASDAQ: EFTR), a leader in the development of selective translation regulator inhibitors (STRIs) for the treatment of cancer, today announced a poster presentation of new clinical data from dose escalation and Phase 2 expansion cohorts of a Phase 1/2 clinical study of zotatifin in patients with estrogen receptor positive (ER+) metastatic breast cancer (mBC) at the San Antonio Breast Cancer Symposium 2023 Annual Meeting.
-
eFFECTOR Therapeutics Reports Third Quarter 2023 Financial Results and Provides Corporate Update
11/13/2023
eFFECTOR Therapeutics, Inc. (NASDAQ: EFTR), a leader in the development of selective translation regulator inhibitors (STRIs) for the treatment of cancer, today reported financial results for the third quarter ended September 30, 2023 and provided a corporate update.
-
eFFECTOR Therapeutics to Participate in Fireside Chat at 2023 Stifel Healthcare Conference
11/6/2023
eFFECTOR Therapeutics, Inc. today announced that the Company will participate in a fireside chat discussion and host 1x1 meetings at the 2023 Stifel Healthcare Conference taking place November 14-15, 2023 in New York, NY.
-
eFFECTOR Therapeutics to Collaborate with the Northwestern University Division of Hematology and Oncology on an Investigator-Initiated Phase 1 Dose Escalation Trial Evaluating Tomivosertib
10/24/2023
eFFECTOR Therapeutics, Inc. today announced the initiation of dosing in an investigator-initiated Phase 1 dose escalation trial evaluating tomivosertib in patients with relapsed/refractory Acute Myeloid Leukemia (AML).
-
eFFECTOR Therapeutics Appoints Caroline Loewy to Board of Directors
9/11/2023
eFFECTOR Therapeutics, Inc. (NASDAQ: EFTR), a leader in the development of selective translation regulator inhibitors (“STRIs”) for the treatment of cancer, today announced the addition of Caroline Loewy to its Board of Directors and her election as Chair of the Board’s Audit Committee.
-
eFFECTOR Therapeutics to Participate in Upcoming September 2023 Investor Conferences
8/30/2023
eFFECTOR Therapeutics, Inc., a leader in the development of selective translation regulator inhibitors for the treatment of cancer, announced that the management team will participate in and host 1x1 meetings at the following upcoming investor conferences.
-
eFFECTOR Therapeutics Reports Second Quarter 2023 Financial Results and Provides Corporate Update
8/8/2023
eFFECTOR Therapeutics, Inc., a leader in the development of selective translation regulator inhibitors for the treatment of cancer, reported financial results for the second quarter ended June 30, 2023 and provided a corporate update.
-
eFFECTOR Therapeutics Raises a Total of $16.2 Million in Gross Proceeds from Two Recent Registered Direct Offerings
6/8/2023
eFFECTOR Therapeutics, Inc. announced that it has closed its previously announced $8.7 million registered direct offering for the purchase and sale of an aggregate of 7,764,445 shares of its common stock, at a purchase price of $1.125 per share, priced at-the-market under Nasdaq rules.
-
eFFECTOR Therapeutics Announces $8.7 Million Registered Direct Offering Priced At-The-Market Under Nasdaq Rules
6/7/2023
eFFECTOR Therapeutics, Inc. today announced that it has entered into a definitive agreement with a single healthcare-focused institutional investor for the purchase and sale of an aggregate of 7,764,445 shares of its common stock.
-
eFFECTOR Therapeutics Announces $7.5 Million Registered Direct Offering Priced At-The-Market Under Nasdaq Rules
5/26/2023
eFFECTOR Therapeutics, Inc. announced that it has entered into a definitive agreement with a single healthcare-focused institutional investor for the purchase and sale of an aggregate of 11,450,382 shares of its common stock, at a purchase price of $0.655 per share, in a registered direct offering priced at-the-market under Nasdaq rules.